Καναδάς - Αγγλικά - Health Canada

omega laboratories limited - octreotide (octreotide acetate) - solution - 200mcg - octreotide (octreotide acetate) 200mcg - miscellaneous therapeutic agents

Νέα Ζηλανδία - Αγγλικά - Medsafe (Medicines Safety Authority)

max health limited - octreotide acetate 0.112 mg/ml equivalent to octreotide 100 mcg/ml - solution for injection - 100 mcg/ml - active: octreotide acetate 0.112 mg/ml equivalent to octreotide 100 mcg/ml excipient: glycine hydrochloric acid mannitol water for injection - symptomatic control and reduction of growth hormone (gh) and igf-1 plasma levels in patients with acromegaly who are inadequately controlled by surgery or radiotherapy. octreotide treatment is also indicated for acromegalic patients unfit or unwilling to undergo surgery, or in the interim period until radiotherapy becomes fully effective.

Νέα Ζηλανδία - Αγγλικά - Medsafe (Medicines Safety Authority)

max health limited - octreotide acetate 0.056 mg/ml equivalent to octreotide 50 mcg/ml - solution for injection - 50 mcg/ml - active: octreotide acetate 0.056 mg/ml equivalent to octreotide 50 mcg/ml excipient: glycine hydrochloric acid mannitol water for injection - symptomatic control and reduction of growth hormone (gh) and igf-1 plasma levels in patients with acromegaly who are inadequately controlled by surgery or radiotherapy. octreotide treatment is also indicated for acromegalic patients unfit or unwilling to undergo surgery, or in the interim period until radiotherapy becomes fully effective.

Νέα Ζηλανδία - Αγγλικά - Medsafe (Medicines Safety Authority)

max health limited - octreotide acetate 0.56 mg/ml equivalent to octreotide 500 mcg/ml - solution for injection - 500 mcg/ml - active: octreotide acetate 0.56 mg/ml equivalent to octreotide 500 mcg/ml excipient: glycine hydrochloric acid mannitol water for injection - symptomatic control and reduction of growth hormone (gh) and igf-1 plasma levels in patients with acromegaly who are inadequately controlled by surgery or radiotherapy. octreotide treatment is also indicated for acromegalic patients unfit or unwilling to undergo surgery, or in the interim period until radiotherapy becomes fully effective.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - octreotide, quantity: 20 mg - injection, modified release - excipient ingredients: polyglactin; mannitol - acromegaly for the symptomatic control and reduction of growth hormone and igf-1 plasma levels in patients with acromegaly, including those who are inadequately controlled by surgery, radiotherapy, or dopamine agonist treatment but who are adequately controlled on s.c. treatment with octreotide. octreotide depot is also indicated in acromegalic patients unfit or unwilling to undergo surgery, or in the interim period until radiotherapy becomes fully effective.,gastro-entero-pancreatic tumours for the relief of symptoms associated with the following functional tumours of the gastro-enteropancreatic endocrine system: ? carcinoid tumours with features of the carcinoid syndrome ? vasoactive intestinal peptide secreting tumours (vipomas) in patients who are adequately controlled on subcutaneous treatment with octreotide octreotide depot is not curative in these patients.,advanced neuroendocrine tumours of the midgut treatment of patients with progression of well-differentiated, advanced neuroendocrine tumours of the midgut or suspected midgut origin.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - octreotide, quantity: 30 mg - injection, modified release - excipient ingredients: polyglactin; mannitol - acromegaly for the symptomatic control and reduction of growth hormone and igf-1 plasma levels in patients with acromegaly, including those who are inadequately controlled by surgery, radiotherapy, or dopamine agonist treatment but who are adequately controlled on s.c. treatment with octreotide. octreotide depot is also indicated in acromegalic patients unfit or unwilling to undergo surgery, or in the interim period until radiotherapy becomes fully effective.,gastro-entero-pancreatic tumours for the relief of symptoms associated with the following functional tumours of the gastro-enteropancreatic endocrine system: ? carcinoid tumours with features of the carcinoid syndrome ? vasoactive intestinal peptide secreting tumours (vipomas) in patients who are adequately controlled on subcutaneous treatment with octreotide octreotide depot is not curative in these patients.,advanced neuroendocrine tumours of the midgut treatment of patients with progression of well-differentiated, advanced neuroendocrine tumours of the midgut or suspected midgut origin.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - octreotide, quantity: 10 mg - injection, modified release - excipient ingredients: polyglactin; mannitol - acromegaly for the symptomatic control and reduction of growth hormone and igf-1 plasma levels in patients with acromegaly, including those who are inadequately controlled by surgery, radiotherapy, or dopamine agonist treatment but who are adequately controlled on s.c. treatment with octreotide. octreotide depot is also indicated in acromegalic patients unfit or unwilling to undergo surgery, or in the interim period until radiotherapy becomes fully effective.,gastro-entero-pancreatic tumours for the relief of symptoms associated with the following functional tumours of the gastro-enteropancreatic endocrine system: ? carcinoid tumours with features of the carcinoid syndrome ? vasoactive intestinal peptide secreting tumours (vipomas) in patients who are adequately controlled on subcutaneous treatment with octreotide octreotide depot is not curative in these patients.,advanced neuroendocrine tumours of the midgut treatment of patients with progression of well-differentiated, advanced neuroendocrine tumours of the midgut or suspected midgut origin.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - octreotide -

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - octreotide -

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - octreotide -